EUVIMEDEUVIMED entdecken
Open Access

225 Ac/ 89 Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4–Positive Triple-Negative Breast Cancer

Hanan Babeker, Fabrice Ngoh Njotu, Jessica Pougoue Ketchemen, Alissar Monzer, Anjong Florence Tikum, Alireza Doroudi, Emmanuel Nwangele, Maruti Uppalapati, Humphrey Fonge

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Hanan Babeker und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. Hauptthemen laut MEDLINE: Immunoconjugates, Triple Negative Breast Neoplasms, Radioisotopes, Zirconium. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nectin-4 is an overexpressed biomarker in 60%-70% of triple-negative breast cancer (TNBC) cases and an ideal target for radiotherapy and PET imaging. In this study, theranostic radioimmunoconjugates were developed using a fully human anti-nectin-4 antibody (N4MU01). The imaging properties and therapeutic effectiveness of the radioimmunoconjugates were evaluated using TNBC models.

Methods

N4MU01 was radiolabeled with 89Zr and 225Ac for imaging and radiotherapy, respectively, using TNBC xenograft and syngeneic models. Biodistribution and PET imaging of the [89Zr]Zr-deferoxamine (DFO)-N4MU01 radioimmunoconjugate was studied in mice bearing nectin-4-positive xenografts. Dosimetry and toxicity of [225Ac]Ac-Macropa-N4MU01 were studied in naïve BALB/c mice, and the therapeutic efficacy was evaluated with two doses of 13 or two doses of 18.6 kBq, administered 10 d apart in athymic BALB/c nude mice bearing either a human TNBC MDA-MB-468 xenograft or a human nectin-4-transfected 4T1 (4T1.nectin-4) syngeneic allograft.

Results

The pharmacokinetic profile of the [89Zr]Zr-DFO-N4MU01 radioimmunoconjugate showed biphasic distribution with a moderate elimination half-life of 63 h. PET imaging and biodistribution of [89Zr]Zr-DFO-N4MU01 in mice bearing the MDA-MB-468 xenograft showed high tumor uptake of 13.2 ± 1.12 percent injected activity per gram at 120 h. [225Ac]Ac-Macropa-N4MU01 was effectively internalized in MDA-MB-468 and was cytotoxic to the cells with a 50% inhibition concentration of 1.2 kBq/mL. Toxicity studies revealed that 15 kBq of [225Ac]Ac-Macropa-N4MU01 was generally well tolerated, as indicated by hematologic, blood chemistry, and histopathologic analysis. Mice bearing MDA-MB-468 and 4T1.nectin-4 xenografts treated with 13 kBq of [225Ac]Ac-Macropa-N4MU01 had 100% (6/6) and 83.3% (5/6) complete tumor remissions, respectively.

Conclusion

The specific tumor uptake and remarkable effectiveness against aggressive TNBC tumors are very promising and warrant the clinical development of N4MU01 radioimmunoconjugates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesTriple Negative Breast NeoplasmsRadioisotopesZirconiumCell Adhesion MoleculesActiniumTheranostic NanomedicineAnimalsHumansMiceFemaleCell Line, TumorTissue DistributionPositron-Emission TomographyMice, Inbred BALB CIsotope LabelingNectins

Stichwörter der Autor:innen

PET/CThuman anti–nectin-4 antibodynectin-4radioimmunoconjugatestargeted α-particle therapytriple-negative breast cancer

Substanzen

ImmunoconjugatesRadioisotopesZirconiumCell Adhesion MoleculesZirconium-89ActiniumNECTIN4 protein, humanActinium-225Nectins

Autor:innen und Institutionen

  • Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Axe Oncologie, Centre de Recherche du CHU de Québec-Université Laval, Québec, Quebec, Canada; and.
  • Faculté de Pharmacie, Université Laval, Ferdinand Andry Pavillon, Québec City, Quebec, Canada.
  • Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; humphrey.fonge@crchudequebec.ulaval.ca maruti.uppalapati@usask.ca.
  • Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; humphrey.fonge@crchudequebec.ulaval.ca maruti.uppalapati@usask.ca.

Zitieren

APA

Babeker, H., Njotu, F. N., Pougoue Ketchemen, J., Monzer, A., Tikum, A. F., Doroudi, A., Nwangele, E., Uppalapati, M., & Fonge, H. (2025). 225 Ac/ 89 Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4–Positive Triple-Negative Breast Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268387

Vancouver

Babeker H, Njotu FN, Pougoue Ketchemen J, Monzer A, Tikum AF, Doroudi A, et al. 225 Ac/ 89 Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4–Positive Triple-Negative Breast Cancer. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268387

BibTeX
@article{Babeker2025,
  author = {Babeker, Hanan and Njotu, Fabrice Ngoh and Pougoue Ketchemen, Jessica and Monzer, Alissar and Tikum, Anjong Florence and Doroudi, Alireza and Nwangele, Emmanuel and Uppalapati, Maruti and Fonge, Humphrey},
  title = {225 Ac/ 89 Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4–Positive Triple-Negative Breast Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268387}
}
Kostenlos starten →